Nasal Polyposis Pipeline Insight
DelveInsight’s, “Nasal Polyposis - Pipeline Insight, 2022,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Nasal Polyposis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Nasal Polyposis Understanding
Nasal Polyposis: Overview
A nasal polyp (also called nasal polyposis) is a benign (noncancerous) tumor that grows from the lining of the nose or sinuses. These polyps usually occur in both the right and left nasal passages and obstruct the flow of air. They can make your nose feel stuffy, and can decrease your sense of smell. Not all growths in the nose are polyps. Nasal polyps may result from chronic (long-lasting) inflammation of the lining of the nose, although they often occur for no apparent reason. People with chronic hay fever (allergic rhinitis) are more likely than others to develop nasal polyps. In addition, nasal polyps commonly develop in children with cystic fibrosis.
"Nasal Polyposis - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nasal Polyposis pipeline landscape is provided which includes the disease overview and Nasal Polyposis treatment guidelines. The assessment part of the report embraces, in depth Nasal Polyposis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nasal Polyposis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Nasal Polyposis R&D. The therapies under development are focused on novel approaches to treat/improve Nasal Polyposis.
Nasal Polyposis Emerging Drugs Chapters
This segment of the Nasal Polyposis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nasal Polyposis Emerging Drugs
Benralizumab is a monoclonal antibody that attracts natural killer cells via antibody-dependent cellular cytotoxicity activity (ADCC activity) to induce direct and rapid depletion of eosinophils in the blood and in the airway. The drug is in phase 3 of clinical trials for the treatment of severe nasal polyposis.
AK001 is a therapeutic antibody that targets a receptor present on eosinophils and mast cells. Binding of antibody to this receptor causes inhibition of mast cell activity and selective depletion of activated eosinophils. AK001's action is highly specific to mast cells and eosinophils and has potential to be of benefit in a wide spectrum of conditions where these cells are involved. It is currently in phase 2 of clinical trial for the treatment of nasal polyposis.
Further product details are provided in the report……..
Nasal Polyposis: Therapeutic Assessment
This segment of the report provides insights about the different Nasal Polyposis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Nasal Polyposis
There are approx. 4+ key companies which are developing the therapies for Nasal Polyposis. The companies which have their Nasal Polyposis drug candidates in the most advanced stage, i.e. phase III include AstraZeneca.
DelveInsight’s report covers around 4+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Nasal Polyposis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Nasal Polyposis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nasal Polyposis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nasal Polyposis drugs.
Nasal Polyposis Report Insights
- Nasal Polyposis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Nasal Polyposis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Nasal Polyposis drugs?
- How many Nasal Polyposis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nasal Polyposis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nasal Polyposis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Nasal Polyposis and their status?
- What are the key designations that have been granted to the emerging drugs?